

Guangyu An

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1884717/guangyu-an-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51
papers

791
citations

17
h-index

26
g-index

52
ext. papers

1,035
ext. citations

4.9
avg, IF

4.09
L-index

#	Paper	IF	Citations
51	Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/ECatenin activity and cancer stemness.. <i>Cancer Letters</i> , 2022 , 531, 83-83	9.9	2
50	Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal adenocarcinoma.. <i>Translational Oncology</i> , 2022 , 17, 101317	4.9	1
49	Establishment of a Competing Risk Nomogram in Patients with Pulmonary Sarcomatoid Carcinoma.. <i>Technology in Cancer Research and Treatment</i> , 2022 , 21, 15330338211068960	2.7	0
48	Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021 , 11, 739263	5.3	0
47	DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway. <i>Molecular Cancer Research</i> , 2021 , 19, 1980-1991	6.6	1
46	Geographic heterogeneity in the outcomes of patients receiving immune checkpoint inhibitors for advanced solid tumors: a meta-analysis.. <i>Translational Cancer Research</i> , 2021 , 10, 310-326	0.3	
45	Lymphocyte-to-monocyte ratio combined with CA19-9 for predicting postoperative recurrence of colorectal cancer in patients with diabetes. <i>Journal of Clinical Laboratory Analysis</i> , 2021 , 35, e23944	3	2
44	Combination of anlotinib and gemcitabine promotes the G0/G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma in vitro. <i>Journal of Clinical Laboratory Analysis</i> , 2021 , 35, e23986	3	3
43	Development and Validation of a Prognostic Gene Signature Correlated With M2 Macrophage Infiltration in Esophageal Squamous Cell Carcinoma.. <i>Frontiers in Oncology</i> , 2021 , 11, 769727	5.3	6
42	Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 3162-3171	12.9	8
41	Reverse engineering a predictive signature characterized by proliferation, DNA damage, and immune escape from stage I lung adenocarcinoma recurrence. <i>Acta Biochimica Et Biophysica Sinica</i> , 2020 , 52, 638-653	2.8	1
40	Disruption of Core 1-mediated O-glycosylation oppositely regulates CD44 expression in human colon cancer cells and tumor-derived exosomes. <i>Biochemical and Biophysical Research Communications</i> , 2020 , 521, 514-520	3.4	10
39	Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer. <i>Life Sciences</i> , 2020 , 241, 117150	6.8	13
38	The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy. <i>International Immunopharmacology</i> , 2020 , 88, 106972	5.8	11
37	Cyclophilin B overexpression predicts a poor prognosis and activates metastatic pathways in colon cancer.. <i>Translational Cancer Research</i> , 2020 , 9, 3573-3585	0.3	0
36	O-glycans on death receptors in cells modulate their sensitivity to TRAIL-induced apoptosis through affecting on their stability and oligomerization. <i>FASEB Journal</i> , 2020 , 34, 11786-11801	0.9	11
35	Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. <i>International Immunopharmacology</i> , 2020 , 87, 106770	5.8	2

34	Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer. <i>Journal of Oncology</i> , 2019 , 2019, 6402925	4.5	18
33	DCLK1 Plays a Metastatic-Promoting Role in Human Breast Cancer Cells. <i>BioMed Research International</i> , 2019 , 2019, 1061979	3	13
32	Extracellular vesicle-delivered miR-505-5p, as a diagnostic biomarker of early lung adenocarcinoma, inhibits cell apoptosis by targeting TP53AIP1. <i>International Journal of Oncology</i> , 2019 , 54, 1821-1832	4.4	9
31	Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019 , 8, 989-999	4.4	16
30	Tn antigen promotes human colorectal cancer metastasis via H-Ras mediated epithelial-mesenchymal transition activation. <i>Journal of Cellular and Molecular Medicine</i> , 2019 , 23, 2083-2092	5.6	14
29	High pretreatment plasma D-dimer levels are associated with shorter overall survival in patients with small cell lung cancer. <i>Journal of International Medical Research</i> , 2019 , 47, 215-224	1.4	13
28	Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. <i>International Journal of Cancer</i> , 2018 , 143, 1162-1175	7.5	33
27	T-Synthase Deficiency Enhances Oncogenic Features in Human Colorectal Cancer Cells via Activation of Epithelial-Mesenchymal Transition. <i>BioMed Research International</i> , 2018 , 2018, 9532389	3	10
26	Aberrant O-glycosylation contributes to tumorigenesis in human colorectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2018 , 22, 4875-4885	5.6	27
25	CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma. <i>Oncology Reports</i> , 2018 , 40, 2023-2035	3.5	16
24	Correlation of Tn antigen expression with mucins in Chinese patients with colorectal cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2018 , 11, 1562-1568	1.4	
23	Association between plasma fibrinogen and survival in patients with small-cell lung carcinoma. <i>Thoracic Cancer</i> , 2018 , 9, 146-151	3.2	22
22	NuRD subunit MTA1 interacts with the DNA non-homologous end joining Ku complex in cancer cells.. <i>RSC Advances</i> , 2018 , 8, 35218-35225	3.7	1
21	RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018 , 2018, 4248971	2.8	22
20	Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells. <i>Molecular Cancer</i> , 2017 , 16, 30	42.1	51
19	Upregulated NNT-AS1, a long noncoding RNA, contributes to proliferation and migration of colorectal cancer cells in vitro and in vivo. <i>Oncotarget</i> , 2017 , 8, 3441-3453	3.3	47
18	DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 2131-40	4.9	44
17	Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem-like Cells Marked by DCLK1 Kinase. <i>Cancer Research</i> , 2016 , 76, 4090-9	10.1	22

16	The clinical and prognostic significance of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy. <i>Tumor Biology</i> , 2016 , 37, 10427-33	2.9	52
15	MicroRNA-375 suppresses human colorectal cancer metastasis by targeting Frizzled 8. <i>Oncotarget</i> , 2016 , 7, 40644-40656	3.3	38
14	Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study. <i>Journal of Thoracic Disease</i> , 2016 , 8, 1645-52	2.6	20
13	Tanshinone IIA Protects against Dextran Sulfate Sodium- (DSS-) Induced Colitis in Mice by Modulation of Neutrophil Infiltration and Activation. <i>Oxidative Medicine and Cellular Longevity</i> , 2016 , 2016, 7916763	6.7	15
12	Dysregulation of long non-coding RNA profiles in human colorectal cancer and its association with overall survival. <i>Oncology Letters</i> , 2016 , 12, 4068-4074	2.6	33
11	Ablation of Doublecortin-Like Kinase 1 in the Colonic Epithelium Exacerbates Dextran Sulfate Sodium-Induced Colitis. <i>PLoS ONE</i> , 2015 , 10, e0134212	3.7	37
10	Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line. <i>OncoTargets and Therapy</i> , 2015 , 8, 1603-10	4.4	9
9	Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma. <i>Oncology Letters</i> , 2015 , 10, 1171-1175	2.6	4
8	Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells. <i>PLoS ONE</i> , 2015 , 10, e0118933	3.7	35
7	Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2015 , 24, 301-7	1.4	18
6	Expression profile of mucin-associated sialyl-Tn antigen in Chinese patients with different colorectal lesions (adenomas, carcinomas). <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 11549-54	1.4	8
5	Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015 , 8, 14595-603		56
4	The role of fucosylation in the promotion of endothelial progenitor cells in neovascularization and bone repair. <i>Biomaterials</i> , 2014 , 35, 3777-85	15.6	7
3	Significance of p85 expression as a prognostic factor for patients with breast cancer. <i>Oncology Letters</i> , 2014 , 8, 1657-1661	2.6	3
2	Role of a genetic variant on the 15q25.1 lung cancer susceptibility locus in smoking-associated nasopharyngeal carcinoma. <i>PLoS ONE</i> , 2014 , 9, e109036	3.7	3
1	Exploratory study on the correlation between 14 lung cancer-related gene expression and specific clinical characteristics of NSCLC patients. <i>Molecular and Clinical Oncology</i> , 2013 , 1, 887-893	1.6	4